Manoli I, Alesci S, Blackman MR, Su YA, Rennert OM, Chrousos GP
Published: August 6, 2025 The treatment landscape for childhood obesity is evolving with the introduction of glucagon-like peptide-1 (GLP-1) receptor agonists in pediatrics
J., & Amrein, R
Graphical Abstract Similar content being viewed by others Introduction Immunomodulation is transforming the treatment landscape of type 1 diabetes [1, 2]
Here we show that lobeline delays SG dissolution post-hypoxia in a dose-dependent manner, leading to a higher percentage of cells containing SGs, an increased number of SGs per cell, sustained ISR activation and reduced protein synthesis
A collagen dressing with GHK-Cu accelerated the healing of wounds in both healthy and diabetic rats